Effects of a snack enriched with carob and Undaria pinnatifida (wakame) on metabolic parameters in a double blind, randomized clinical trial in obese patients by Izaola, Olatz et al.
Nutrición
Hospitalaria
Trabajo Original Obesidad y síndrome metabólico
ISSN (electrónico): 1699-5198 - ISSN (papel): 0212-1611 - CODEN NUHOEQ S.V.R. 318
Effects of a snack enriched with carob and Undaria pinnatifida (wakame) on metabolic 
parameters in a double blind, randomized clinical trial in obese patients 
Efectos de un aperitivo enriquecido con algarroba y Undaria pinnatifida (wakame) sobre los parámetros 
bioquímicos en un ensayo clínico doble ciego y aleatorizado de pacientes obesos
Olatz Izaola1, David Primo1, Daniel Rico Bargés2, Ana Belén Martín-Diana2, Cristina Martínez Villaluenga3, Jónatan Miranda4, and Daniel 
Antonio de Luis1 
1Department of Endocrinology and Nutrition, Hospital Clínico Universitario & Centro de Investigación de Endocrinología y Nutrición Clínica. Facultad de Medicina. Universidad 
de Valladolid. Valladolid, Spain. 2Instituto Tecnológico Agrario de Castilla y León. Subdirección de Investigación y Tecnología. Consejería de Agricultura y Ganadería. Valladolid, 
Spain. 3Department of Food Characterization, Quality and Safety. Instituto de Ciencia y Tecnología de Alimentos y Nutrición (ICTAN-CSIC). Madrid, Spain. 4Nutrition and Obesity 







Introduction: the composition of snack foods likely influences the overall effect that snacking has on metabolism and obesity. The objective of 
the current study was to assess the responses to two different snacks, one of them supplemented with wakame and carobs, on cardiovascular 
risk factors, satiety, and subsequent food intake in obese subjects with metabolic syndrome.
Material and methods: forty patients were randomized in a clinical trial (NCT03420989, clinicaltrial.gov) to group I (enriched snack, n = 16) 
or group II (control snack, n = 16). At baseline and after 8 weeks biochemical parameters, dietary intakes, and nutritional status were assessed. 
The subjects also rated their feelings of satiety/hunger with a test meal.
Results: no differences were detected in anthropometric parameters between both snacks. Changes in other parameters were detected in 
patients with enriched snacks, with a significant decrease in LDL-cholesterol by 7.4 % (intervention snack, -8.9 ± 2.3 mg/dL vs control snack, 
-0.9 ± 3.3 mg/dL; p = 0.03), in total cholesterol by 5.8 % (intervention snack, -10.4 ± 2.9 mg/dL vs control snack, -1.4 ± 3.2 mg/dL; p = 
0.02), and in resistin level by 15.9 % (intervention snack, -1.0 ± 0.2 mg/dL vs control snack, -0.1 ± 0.3 mg/dL: p = 0.03). After the test meal, 
satiety scores (after 20 min and 40 min) were higher than fasting levels in both groups. The same results were obtained with the 100-mm, 
5-point visual satiety scale.
Conclusion: our study indicates that a wakame- and carob-enriched snack induces a significant decrease in total cholesterol, LDL-cholesterol, 









Introducción: la composición de los “snacks” probablemente influya en el efecto que produce su consumo sobre los marcadores metabólicos y 
la obesidad. El objetivo del presente estudio fue evaluar las respuestas a dos snacks, uno de ellos suplementado con wakame y algarroba, sobre 
factores de riesgo cardiovascular, saciedad y posterior ingesta de alimentos, en sujetos obesos con síndrome metabólico.
Material y métodos: se aleatorizaron 40 pacientes en el ensayo clínico NCT03420989 (clinicaltrial.gov) para participar en el grupo I (snack 
enriquecido, n = 16) o el grupo II (snack de control, n = 16). Antes y después de 8 semanas se determinaron los parámetros bioquímicos, las 
ingestas dietéticas y el estado nutricional. A los sujetos también se les evaluó la saciedad y el apetito con una comida de prueba.
Resultados: no se detectaron diferencias en los parámetros antropométricos con ambos snacks. Se detectaron cambios en los parámetros 
bioquímicos de los pacientes que recibieron snacks enriquecidos, con una disminución significativa del colesterol-LDL del 7,4 % (snack de 
intervención, -8,9 ± 2,3 mg/dl vs. snack de control, -0,9 ± 3,3 mg/dl; p = 0,03), del colesterol total del 5,8 % (snack de intervención, -10,4 
± 2,9 mg/dl vs. snack de control, -1,4 ± 3,2 mg/dl; p = 0,02) y de los niveles de resistina del 15,9 % (snack de intervención, -1,0 ± 0,2 mg/
dl vs. snack de control, -0,1 ± 0,3 mg/dl; p = 0,03). Después de la comida de prueba, las puntuaciones de saciedad (a los 20 min y 40 min) 
fueron más altas que el nivel de ayuno en ambos grupos. Los resultados fueron similares con la escala de saciedad visual de 5 puntos y 100 mm.
Conclusión: nuestro estudio muestra que un snack enriquecido con wakame y algarroba produce una disminución significativa de los niveles 
de colesterol total, colesterol-LDL y resistina frente a un snack de control, sin efectos sobre el consumo de alimentos, otros parámetros cardio-
vasculares y los parámetros antropométricos.
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INTRODUCTION 
Snack foods are substantial contributors to daily energy 
intake. In a study, more than 80 % of participants reported 
snacking at least once per day, and more than 50 % of par-
ticipants reported snacking multiple times per day (1). Inves-
tigators have demonstrated that subjects commonly choose 
chocolate, bakery goods, sweets, milk products, salad products 
and cookies during snacking episodes (2). Some researchers 
(3,4) reported that obese subjects consume snacks more fre-
quently than healthy-weight subjects do. The composition of 
snack foods likely influences the overall effects that snacking 
has on metabolism and obesity. 
Obesity represents a major pandemic with a multifactorial 
origin, showing an association with various cardiovascular risk 
factors, high mortality, and high healthcare costs (5). Metabolic 
syndrome accompanies obesity and worsens the prognosis of 
these patients, increasing their cardiovascular risk. Diet plays 
a major role in preventing and managing metabolic syndrome 
(6). One of the problems with dietary therapy is lack of patient 
adherence, as well as lack of perception of the benefits provided 
by the control of cardiovascular risk factors. One possibility is 
including in the diet snacks containing fiber or new ingredients 
to control satiety and dietary intake (7). Marine algae could be 
one of these new ingredients. Marine algae are divided into two 
groups, namely macroalgae (seaweed) and microalgae. Macroal-
gae are rich in minerals, vitamins, dietary fiber, proteins, poly-
saccharides, and polyphenols. These algae are divided into three 
classes — brown (phaeophytes), red (rhodophytes), and green 
(clorophytes). Brown seaweeds contain bioactive compounds 
such as polyphenols, omega-3 fatty acids, fucosterol, and fucox-
anthin. These components have several properties, including 
anti-inflammatory, anti-diabetic, and antihypertensive activity (8). 
Undaria pinnatifida, commonly known as wakame, is a species of 
brown seaweed containing valuable bioactive organic compounds 
including fucoxanthin (8). Some observational studies reported 
that elderly people who consume more seaweed have lower blood 
pressure (9,10) as compared to individuals with lower seaweed 
intakes. Seaweed supplements of wakame have been used in 
clinical hypertension trials, obtaining a reduction of systolic and 
mean blood pressure (11,12). In another interventional study (13), 
consumption of wakame sporophylls reduced postprandial glu-
cose concentrations. 
Moreover, a high-fiber diet has been linked to decreased car-
diovascular risk factors (14). But little is known about the effect of 
insoluble fiber on these cardiovascular risk factors, especially on 
blood lipids. The carob tree fruit has a high content of insoluble 
fiber and is supposed to have beneficial effects on human health 
(15). For example, in a one-arm study a carob pulp prepara-
tion reduced low-density lipoprotein (LDL) cholesterol in human 
beings (16).
The objective of the current study was to assess the responses 
to two different snacks, one of them enriched with wakame and 
carobs, on cardiovascular risk factors, satiety, and subsequent 
food intake in obese subjects with metabolic syndrome.
MATERIAL AND METHODS 
Forty obese subjects were recruited from the community in 
a randomized, double blind, placebo-controlled, parallel arm 
study; recruitment started in January 2018 and follow-up was 
completed in July 2018. The recruited subjects fulfilled the fol-
lowing criteria: presence of metabolic syndrome according to 
ATP III criteria (17) and body mass index (BMI) ≥ 30 kg/m2; 
no history of coronary events, thyroid disease, renal or hepatic 
disorders, alcoholism, or malignant tumors; and no medications 
known to affect lipid levels received within 6 months before 
the study (hormonal therapy, glucocorticoids, anti-inflammatory 
drugs). Potential obese patients with metabolic syndrome were 
excluded if they were pregnant or taking any of the following 
medications: statins, fibrates, resins, sulfonylureas, bigua-
nides, thiazolidinediones, insulin, glucocorticoids, alpha-block-
ers, converting enzyme inhibitors, and angiotensin II receptor 
antagonists. Subjects needed to fulfill at least 3 of the following 
5 criteria to be diagnosed with metabolic syndrome: elevated 
fasting glucose or treatment for diabetes, elevated triglycerides 
(> 150 mg/dL) or treatment for dyslipemia, low HDL-cholesterol 
< 40 mg/dL [males] or < 50 mg/dL [females], elevated systolic 
or diastolic blood pressure (> 130/85 mmHg or antyhipertensive 
treatment), and increased waist circumference (WC) (> 94 cm 
[males] or > 80 cm [females]). 
The Hospital Ethics Committee (HCUVA Committee) approved 
the study, which was in accordance with the guidelines laid down 
in the Declaration of Helsinki. All participants provided their written 
informed consent. The study was registered in www.clinicaltrial.
gov with code number NCT03420989.
PROCEDURE AND SATIETY SCORES
Patients were randomized (table of numbers) to one of the 
following two groups: snack I (enriched with wakame and car-
ob pod flour, see table I) or snack II (control snack, see table I). 
Each patient received a total of 50 grams of either product per 
day (two packages of 25 g per day), and completed 8 weeks of 
treatment. Snack intake was controlled for 8 weeks, every week, 
and patients were instructed to eat their snacks along the day. The 
methodology was a double-blind, placebo-controlled, parallel arm 
study where neither the patient nor the investigator who followed 
the patient knew which type of snack had been asigned. Only 
the patients who took more than 80 % of the snacks dispensed 
were analyzed.
Patients reported to the laboratory at the same time each day 
following a 10-h fast. Before starting the dietary intervention and 
at the end of the protocol weight, fat mass, blood pressure, fasting 
blood glucose, C-reactive protein (CRP), insulin, insulin resistance 
(HOMA-R), total cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides, thyroid-stimulating hormone (TSH), and adipokine 
(leptin, resistin, adiponectin) levels were measured. 
After their arrival at the laboratory patients were interviewed 
to ensure that they followed the dietary protocol prior to the visit. 
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Subjects rated their feelings of satiety/hunger using a scoring 
system graded from minus 10, to represent extreme hunger, to 
plus 10, to represent extreme satiety (18). Subjects were shown 
a scale with 20 graduations, and asked to indicate how they felt 
regarding hunger or satiety by pointing to the appropriate place 
along the scale. The scale was punctuated with phrases describ-
ing various degrees of hunger and satiety, but subjects were free 
to choose any point along it. A 100-mm, 5-point visual satiety 
scale (19) was used, too. Patients were instructed to place a single 
vertical line on the scale, representing their feeling in response to 
5 questions (grade of hunger, grade of satiety, grade of fullness, 
desire to eat some food, desire to eat something fatty, salty, sweet, 
or savory). The scale was anchored at 0 with “nothing at all” and 
at 100 with “a large amount”. 
Both hunger and satiety scores were recorded before a test 
meal of 25 grams of snacks, immediately after it, and at 20 and 
40 minutes after starting the meal. Patients were instructed to 
eat the test meal (25 grams of snacks) in less than 10 minutes 
with 150 mL of water.
BIOCHEMICAL DETERMINATIONS
Fasting venous blood samples were taken for measurements of 
fasting glucose, total cholesterol, triglycerides, low-density lipo-
protein-cholesterol (LDL-c) and high-density lipoprotein-cholester-
ol (HDL-c) using a biochemical auto-analyzer (Hitachi 7060, Tokyo, 
Japan). LDL-cholesterol was determined using Friedewald’s for-
mula (20). Fasting glucose was determined by the enzymatic 
colorimetric method using glucose oxidase. Fasting insulin was 
measured using the radio-immunoassay method (RIA) (RIA Diag-
nostic Corporation, Los Angeles, CA, USA) with a sensitivity of 
0.5 mIU/L (normal range, 0.5-30 mIU/L) (21). We calculated the 
homeostasis model assessment of insulin resistance (HOMA-IR) 
as follows: HOMA-IR = (insulin x glucose)/22.5 (22). C-reactive 
protein (CRP) was determined by immunoturbimetry (Roche Diag-
nostics GmbH, Mannheim, Germany), with a normal range of (0-7 
mg/dL) and analytical sensitivity of 0.5 mg/dL.
 Leptin was determined by ELISA (Diagnostic Systems Labora-
tories, Inc., Texas, USA) (DSL1023100), with a sensitivity of 0.05 
ng/mL, a normal range of 10-100 ng/mL, and a CV % of 3.5 % 
(23). Adiponectin was determined by ELISA (R&D systems, Inc., 
Minneapolis, USA) (DRP300) with a sensitivity of 0.246 ng/mL, a 
normal range of 8.65-21.43 ng/mL, and a CV % of 3.8 % (24). 
Resistin was determined by ELISA (Biovendor Laboratory, Inc., 
Brno, Czech Republic) (RD191016100) with a sensitivity of 0.2 
ng/mL, a normal range of 4-12 ng/mL (25), and a CV % of 3.2 %. 
TSH was determined by ELISA (Biovendor Laboratory, Inc., Brno, 
Czech Republic) (ab100660) with a sensitivity of 0.1 IU/L, a nor-
mal range of 0.4-4.5 IU/L, and a CV % of 3.8 %.
BLOOD PRESSURE AND ANTHROPOMETRIC 
PARAMETERS 
Mean systolic and diastolic blood pressures were calculated 
by averaging three measurements (Omrom, LA, CA, USA) after 
the subjects had sat for 10 minutes. Body weight was deter-
mined in the morning with the subjects minimally unclothed 
and wearing no shoes. They were measured using digital scales 
(Omrom, LA, CA, USA), and recorded to the nearest 50 g. Height 
was measured with a tape measure (Omrom, LA, CA, USA) 
while the patients were standing with their shoulders in normal 
alignment and wearing no shoes. Body mass index (BMI) was 
calculated as body weight (in kg) divided by height (in m2). 
Waist circumference (WC) was measured at the umbilical level 
with the use of an upstretched tape measure. Bio impedance 
was used to determine body composition with an accuracy of 
5 g (26) (EFG BIA 101 Anniversary, Akern, Italy). This equation 
was used: 0.756 Height2/Resistance) + (0.110 Body mass) + 
(0.107 Reactance) - 5.463. 
DIETARY INTERVENTION
Before and after the intervention with snacks (two packages 
of 25 g per day), patients received prospective serial assess-
ments of nutritional intake with written food records for 3 days. All 
enrolled subjects received instructions to record their daily dietary 
intake for three days including a weekend day. The handling of 
dietary data was by means of a personal computer equipped 
with personal software, incorporating the use of food scales and 
models to enhance portion size accuracy. The records of intake 
and consumption of snacks were reviewed by a dietician and 
analyzed with a computer-based data evaluation system. National 
food composition tables were used as reference (27). The exer-
cise allowed was aerobic, which was previously done by patients 
before entering the study, mainly walking. 
Table I. Snack composition  
(per 100 g; intervention dose, 50 g/day)




Proteins (g) 13.1 11.8
Carbohydrates (g) 38.3 31.4
Fats (g) 18.0 16.0
Saturated (g) 2.9 2.5
Mono-unsaturated (g) 12.4 11.2
Poly-unsaturated (g) 2.6 2.3
Total fiber (g) 24.4 22.9
Soluble fiber (g) 8.8 6.5
Insoluble fiber (g) 15.6 16.4
Wakame (g) 0 0.064
Carob pod flour (g) 0 3.64
Kcal 367.4 365.2
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GASTROINTESTINAL EFFECTS
At dietary intervention patients were asked whether they con-
sidered their bowel habits had changed either quantitatively or 
qualitatively. For a qualitative evaluation, they were asked in the 
last visit whether they considered that the introduction of the 
snack in their diet could have induced diarrhea (yes/no), mete-
orism (yes/no), or vomiting (yes/no). For a quantitative evaluation, 
they were asked about their number of stools per day. 
STATISTICAL ANALYSIS
Sample size was calculated to detect a difference in LDL-cho-
lesterol of 5 % after treatment with a 90 % power and an alpha 
error of 5 % (n = 15 in each group). The results were expressed 
as mean (standard deviation). The normality of variables was ana-
lyzed by the Kolmogorov-Smirnov test. Quantitative variables with 
normal distribution were analyzed with Student’s t-test for both 
paired and unpaired variables. Variables without normal distribu-
tion were analyzed with Wilcoxon’s W-test. The ANOVA test was 
used as needed, with Bonferroni’s test as post-hoc test. Qual-
itative variables were analyzed using the chi-squared test with 
Yates’ correction when appropriate, and Fisher’s test. The area 
under the response curve (AUC) for both hunger/satiety scores 
with the test food (25 g of snacks) was calculated using the trap-
ezoidal method. The strategy of analysis was by intention to treat. 
A p-value lower than 0.05 was considered statistically significant. 
All statistical analyses were performed using the SPSS (version 
19.0) software. 
RESULTS 
Forty patients were included in the protocol (Fig. 1, Consort 
diagram), 32 patients finished the study. The 8 patients exclud-
ed from the analysis had taken less than 80 % of the prescribed 
snacks. Distribution included group I (enriched snack, 8 males and 8 
females with a mean age of 50.7 ± 10.2 years) and group II (control 
snack, 7 males and 9 females with a mean age of 51.4 ± 10.3 
years). No differences in gender or age distribution was observed.
BIOCHEMICAL AND ANTHROPOMETRICAL 
PARAMETERS
The values of anthropometric and biochemical parameters are 
shown in table II and table III, respectively. No differences were 
detected in anthropometric parameters with the dietary interven-
tion. Anthropometric parameters after the introduction of snacks in 
the patients’ usual diet did not change any parameter (Table II). This 
finding is logical because the inclusion of patients in the protocol 
Figure 1. 
Flow chart of patients.
Patients (n = 40)
Excluded (n = 0)
Randomized
Randomized to intervention (n = 20)
Received the intervention (n = 20)
No Received the intervention (n = 0)
Randomized to intervention (n = 20)
Received the intervention (n = 20)
No Received the intervention (n = 0)
Continuing adequate monitoring (n = 20)
Analyzed (n = 16)
Continuing adequate monitoring (n = 20)
Analyzed (n = 16)
Intervention snack Control snack
Follow up
Analysis
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did not alter total energy intake from their diet. With respect to 
biochemical values after the introduction of snacks on the patients’ 
usual diet (Table III), changes were identified in patients with 
enriched snacks, with a significant decrease in LDL-cholesterol 
by 7.4 % (intervention snack, -8.9 ± 2.3 mg/dL vs control snack, 
-0.9 ± 3.3 mg/dL; p = 0.03), in total cholesterol by 5.8 % (inter-
vention snack, -10.4 ± 2.9 mg/dL vs control snack, -1.4 ± 3.2 
mg/dL; p = 0.02), and in resistin by 15.9 % (intervention snack, 
-1.0 ± 0.2 mg/dL vs control snack, -0.1 ± 0.3 mg/dL; p = 0.03). 
DIETARY INTAKE EFFECTS
In the evaluation of dietary intake variables no statistically sig-
nificant differences in baseline values were detected between the 
two groups of snacks (Table III). With respect to the values after 
the introduction of snacks on the patients’ usual diet, in patients 
with both snacks a significantly increase in total fiber and soluble 
fiber dietary intakes was identified, as expected (Table III).
The percentage of consumed snack packages after 8 weeks 
of intervention was 97.8 % in the intervention snack group, and 
96.6 % in the control snack group.
SATIATING EFFECTS
Immediately before the test meal, the baseline hunger/satiety 
score (18) (Table IV) was similar with both the intervention and 
control snacks; the data after 8 weeks of treatment were similar 
in both groups, too. After the test meal, the baseline AUC of this 
Table II. Anthropometric parameters and blood pressure 
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
Age 50.7 ± 10.2 - 51.4 ± 10.3 -
Gender (F/M) 8/8 9/7
BMI 39.8 ± 5.4 39.4 ± 4.5 40.0 ± 4.8 39.8 ± 3.7 
Weight (kg) 110.4 ± 16.3 111.3 ± 12.4 109.4 ± 19.3 108.6 ± 19.4
Fat mass (kg) 49.8 ± 10.3 49.9 ± 8.6 47.8 ± 12.3 47.6 ± 12.6
WC 121.7 ± 10.8 121.5 ± 8.1 124.8 ± 11.8 122.9 ± 9.1
SBP (mmHg) 135.1 ± 11.3 135.9 ± 10.1 139.4 ± 15.3 137.3 ± 12.1 
DBP (mmHg) 85.4 ± 9.3  84.1 ± 7.2 82.6 ± 9.3 81.1 ± 7.2
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure. No statistical differences within the intervention group or 
between groups.
Table III. Biochemical cardiovascular risk factors, TSH, and adipokine levels 
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
Glucose (mg/dL) 101.9 ± 14.9 100.4 ± 12.0 111.9 ± 14.9 113.4 ± 12.0
Total ch. (mg/dL) 196.2 ± 30.4 185.8 ± 28.5* 189.2 ± 42.4 187.8 ± 49.5
LDL-ch. (mg/dL) 120.4 ± 24.7 111.5 ± 21.5* 108.4 ± 40.7 107.5 ± 31.5
HDL-ch. (mg/dL) 49.4 ± 7.3 48.5 ± 7.2 50.2 ± 13.3 49.7 ± 10.2
TG (mg/dL) 145.6 ± 96.4 129.6 ± 46.3 167.2 ± 83.4 166.2 ± 87.6
Insulin (mUI/L) 21.9 ± 10.2 20.8 ± 18.4 20.4 ± 11.5 19.0 ± 8.6
HOMA-IR 5.9 ± 3.1 5.8 ± 4.1 6.1 ± 5.9 5.6 ± 4.3
CRP(mg/dL) 6.0 ± 3.9 6.0 ± 3.1 6.1 ± 4.6 6.1 ± 4.8
TSH (UI/L) 2.6 ± 1.2 3.2 ± 1.5 3.1 ± 2.1 3.2 ± 2.0
Resistin (ng/dL) 6.3 ± 5.2 5.3 ± 5.1* 5.5 ± 2.3 5.4 ± 3.8
Leptin (ng/dL) 78.7 ± 47.4 87.6 ± 47.1 75.1 ± 52.5 65.8 ± 43.1
Adiponectin (ng/dL) 25.7 ± 16.4 27.6 ± 19.1 27.4 ± 15.5 27.9 ± 14.1
Ch: cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglycerides; CRP: C-reactive protein; HOMA-R: homeostasis model of assesment; TSH: 
thyroid-stimulating hormone. * Statistical differences in the same snack group after intervention. No statistical differences between both groups.
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hunger/satiety score was similar both the with intervention and 
control snacks, and the data after 8 weeks of treatment were also 
similar. In both groups the scores (20 min and 40 min) were higher 
than the fasting level. 
The results obtained were similar with the 100-mm, 5-point 
visual satiety scale (19) (Table V). When asked “How is your grade 
of hunger?,” “How is your desire to eat some food?,” and “How is 
your desire to eat something salty, sweet, or savory?” after 20 min 
and 40 min, the subjects responded that they wanted to eat less 
with both snacks, without statistical differences between them. 
After the test meal, the baseline AUCs for these questions were 
similar for both snacks.
When asked “How is your grade of satiety?,” and “How is your 
grade of fullness?” (Table V) after 20 min and 40 min, the sub-
jects gave higher scores with both snacks, without statistical 
differences between snacks. After the test meal, the baseline 
AUCs for these questions were similar for both snacks. 
GASTROINTESTINAL EFFECTS
As regards the effects induced on the digestive tract, no epi-
sodes of diarrhea, meteorism, or related vomiting were reported 
(Table VI). The number of stools per day was similar with both 
snacks, without changes after the intervention.
DISCUSSION
The results of our study indicate that a wakame- and carob-en-
riched snack promoted a greater decrease in total cholesterol, 
LDL-cholesterol, and resistin levels than the control snack, but 
daily food consumption, other cardiovascular parameters, and 
anthropometric parameters were not significantly affected. 
The difference between both snacks is the presence of a small 
amount of wakame and the use of carob flour in the preparation 
Table V. Satiety/hunger using a scoring system graded from minus 10,  
to represent extreme hunger, to plus 10, to represent extreme satiety 
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
AUC score (mm) -2.1 ± 3.1 -1.0 ± 2.7 - 1.6 ± 2 .5 - 2.0 ± 2.2
Score before test meal (mm) -2.5 ± 2.4 -2.3 ± 2.1 - 2.5 ± 2.4 -2.9 ± 1.9
Score 20 min after test meal (mm) -0.2 ± 1.8* 0.1 ± 2.8* -0.2 ± 2.1* -0.5 ± 2.7*
Score 40 min after test meal (mm) 0.6 ± 2.1* 1.2 ± 2.0* 1.1 ± 3.2* 1.3 ± 3.0*
AUC: area under the curve. No statistical differences between snack groups. * Statistical differences in the same snack group (baseline or 8 weeks). 
Table IV. Dietary intakes and exercise
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
Energy (kcal/day) 1728.9 ± 543.1 1844.5 ± 557.2 1823.2 ± 462 1713.7 ± 466.3
CH (g/day) 180.2 ± 54.1 195.8 ± 76.7 174.9 ± 67.8 161.8 ± 52.9
Fat (g/day) 62.5 ± 27.5 68.1 ± 20.7 73.8 ± 23.9 72.1 ± 30.4
Fat-S (g/day) 19.1 ± 9.2 17.8 ± 9.1 21.3 ± 11.5 18.2 ± 9.1
Fat-M (g/day) 26.2 ± 14.2 33.4 ± 11.4 29.4 ± 9.3 31.5 ± 12.1
Fat-P (g/day) 6.6 ± 5.7 7.5 ± 3.1 8.9 ± 4.9 7.1 ± 4.2
Protein (g/day) 81.4 ± 35.4 85.4 ± 32.5 96.8 ± 20.2 89.8 ± 17.3
Total fiber (g/day) 14.5 ± 8.9 23.8 ± 6.1* 12.1 ± 4.3 22.1 ± 6.1*
Soluble fiber (g/day) 2.4 ± 1.1 5.2 ± 1.3* 2.1 ± 0.7 5.3 ± 1.2*
Insoluble fiber (g/day) 12.1 ± 7.1 18.7 ± 5.8* 10.0 ± 3.1 16.7 ± 4.3*
Cholesterol (mg/day) 310.2 ± 193.2 295.5 ± 188.1  315.5 ± 173.1 316.2 ± 183.8
Sodium (mg/day) 1536.2 ± 684.1 1544.1 ± 762.3 1624.2 ± 688.1 1265.5 ± 646.3
Exercise (h/week) 1.6 +/- 1.3 1.2 +/- 1.9 1.9 +/- 0.7 1.8 +/- 1.2
CH: carbohydrates; Fat-S: fat, saturated; Fat-M: fat, mono-unsaturated; Fat-P: fat, poly-unsaturated. * Statistical differences in the same snack group after intervention. 
No statistical differences between both groups.
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of the intervention snack. Therefore, the biochemical differences 
seen in our study may be due to any of the two added nutri-
ents. Previously, some studies were conducted in humans with 
wakame. For example, Tanemura et al. (13) demonstrated that the 
consumption of a high amount of mekaku, another brown sea-
weed (40 g per day), with a white rice-based breakfast reduced 
postprandial glucose concentrations in a group of twelve healthy 
subjects. In this study (13), wakame (70 g per day) did not show 
this antidiabetic effect. These findings indicate the potential role 
of some brown algae as anti-diabetic food. The lack of effect of 
Table VI. The 100-mm, 5-point visual satiety scale 
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
“How is your grade of hunger?”
AUC score (mm) 59.0 ± 20.2 69.9 ± 20.9 81.8 ± 24.1 82.1 ± 18.1
Score before test meal (mm) 26.6 ± 23.4 34.6 ± 21.8 41.8 ± 24.9 38.1 ± 20.1
Score 20’ after test meal (mm) 17.7 ± 17.1* 22.3 ± 22.9*  23.2 ± 21.3* 23.2 ± 23.8*
Score 40’ after test meal (mm) 16.9 ± 17.8* 14.6 ± 18.3* 17.9 ± 21.3* 21.2 ± 21.7*
“How is your grade of satiety?”
AUC score (mm) 126.7 ± 27.1 153.6 ± 30.7 114.2 ± 28.8 118.2 ± 30.9
Score before test meal (mm) 30.0 ± 23.6 42.3 ± 25.1 15.1 ± 19.1 17.4 ± 29.4
Score 20’ after test meal (mm) 47.6 ± 24.1* 53.8 ± 30.0  51.2 ± 29.1* 45.6 ± 28.8*
Score 40’ after test meal (mm) 49.2 ± 27.2* 60.7 ± 34.7 48.7 ± 28.3* 56.8 ± 26.1* 
“How is your grade of fullness?”
AUC score (mm) 127.7 ± 27.1 151.1 ± 30.7 115.7 ± 18.8 116.6 ± 23.9
Score before test meal (mm) 30.7 ± 25.2 40.0 ± 25.1 18.7 ± 20.9 17.5 ± 29.4
Score 20’ after test meal (mm) 46.1 ± 21.1* 50.7 ± 29.8*  46.6 ±27.5* 43.7 ± 26.8*
Score 40’ after test meal (mm) 50.0 ± 29.4* 60.7 ± 34.6* 50.6 ± 28.3* 56.6 ± 26.1*
“How is your desire to eat some food?”
AUC score (mm) 79.5 ± 20.1 80.6 ± 22.7 110.9 ± 28.8 95.3 ± 23.9
Score before test meal (mm) 36.6 ±23.2 41.5 ± 38.1 46.8 ± 31.9 42.5 ± 32.4
Score 20’ after test meal (mm) 20.7 ± 22.1* 23.8 ± 26.0*  23.7 ± 28.5* 28.3 ± 31.8*
Score 40’ after test meal (mm) 22.3 ± 19.2* 16.9 ± 18.6* 20.9 ± 24.8* 24.3 ± 24.1*
“How is your desire to eat something salty, sweet or savory?
AUC score (mm) 99.7 ± 27.1 94.6 ± 29.7 99.2 ± 31.8 99.5 ± 29.9
Score before test meal (mm) 42.3 ± 23.6 45.3 ± 37.1 53.2 ± 33.3 47.5 ± 34.4
Score 20’ after test meal (mm)
27.5 ± 31.7* 25.8 ± 29.7* 20.6 ± 24.5* 21.8 ± 22.1*
Score 40’ after test meal (mm)
AUC: area under the curve. No statistical differences between snack groups. * Statistical differences in the same snack group (baseline or 8 weeks). 
Table VII. Gastrointestinal tolerance
Parameters
Intervention snack Control snack
Baseline 8 weeks Baseline 8 weeks
Number of stools per day 1.2 ± 2.3 1.1 ± 0.9 1.6 ± 1.2 1.7 ± 1.3
Related vomiting, % 0 0 0 0
Meteorism, % 0 0 0 0
Diarrhea, % 0 0 0 0
No statistical differences within the intervention group or between both groups.
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wakame on glucidic metabolism is consistent with the findings 
of our study.
Teas et al. (28), in 27 subjects with at least one symptom of 
metabolic syndrome, reported a decrease in systolic blood pres-
sure and waist circumference after treatment with 6 g per day of 
seaweed powder (77 µg of wakame) for 4 weeks. In our study, we 
did not find any differences in blood pressure or anthropometric 
variables, probably due to the lower dose of wakame used in 
the intervention snack. Teas et al. (28) proposed two potential 
mechanism to explain their interesting results: upregulation of 
the uncoupling protein (UCP-1), and a direct effect of fucoids 
(the sulphated polysaccharides found almost exclusively in brown 
seaweeds) on adipose cell differentiation (29).
To date in the literature, a direct effect of wakame on the lipid 
profile has not been described in human beings. Only one study 
in rats with a high dose of wakame sporophylls (30) showed a 
modest improvement in total cholesterol and very low-density 
lipoprotein-cholesterol. Therefore, we surmise a direct effect of 
carob flour on the metabolic changes included in our design. 
Previously, Papakonstatinou et al. (31) demonstrated in a random-
ized, cross-over study (50 healthy subjects) that consumption of 
a carob snack as preload decreased the glycemic response to a 
following meal as well as hunger sensation. The preload carob 
snack was 65 g (a higher amount than our snack), and the compo-
sition of this snack had 65 g of carob powder per 100 g, whereas 
our snack had only 3.6 g per 100 g. These differences in grams 
between test meals and snack composition could explain the 
lack of results on satiety and glucose metabolism in our protocol. 
Bañuls et al. (32) showed that supplementation for 12 weeks with 
a carob-enriched beverage also induced a significant improve-
ment in glucose metabolism parameters in healthy subjects. In the 
two previous studies (31,32) lipid metabolism was not explored. 
Later, Zurift et al. (33), in a randomized, double blind clinical trial 
of a carob preparation in 58 hypercholesterolemic subjects with 
a 6 week intervention phase, reported a significant decrease in 
LDL-cholesterol (10.5 %). The intervention was shorter than ours 
but the total daily amount of carob was higher than in our design 
(15 g per day of carob pulp preparation).
In another randomized clinical trial Ruiz-Roso et al. (34) report-
ed that consumption for 4 weeks of 8 g of insoluble fiber from 
carob (enriched milk) produced beneficial effects on the human 
lipid profile with a reduction in LDL-cholesterol (22.5 %). This 
study was performed in volunteers with hypercholesterolemia. 
The mechanism involved in the reduction of LDL-cholesterol by 
dietary fiber from carob is a sum of several effects: a reduction in 
the absorption of fats, an increase in the synthesis and excretion 
of bile acids, an inhibition of the endogenous synthesis of choles-
terol from short fatty acids generated in the large intestine, and 
modifications in the amount of hepatic LDL receptors (34,35). The 
effect on LDL-cholesterol levels in these previous studies (33,34) 
was higher than in our design, which may be explained by the fact 
that all these potential mechanisms were enhanced in subjects 
with higher levels of cholesterol (hypercholestoremic subjects) 
when compared to subjects with average basal values, as was the 
case with our obese subjects with metabolic syndrome. Another 
possible explanation is that our snack contained carob pod flour, 
unlike other studies that used carob pulp. 
It is important to point out that the intervertion for 8 weeks 
with a functional snack caused a decrease in resistin levels. 
Possibly, as described in other studies, the effect of wakame on 
adipocytes (29) may be explained with a paracrine or autocrine 
action, without affecting total body fat. In the previously reviewed 
studies with wakame or carob no levels of adipokines were 
ever determined, therefore we cannot compare our results with 
theirs (28-36). Only one study in rats (37) reported, after high-
dose supplementation with wakame, an increase in adiponectin 
serum concentration and expression, as well as a downregula-
tion of IL-6 expression.
This heterogeneity of results in the literature after carob and 
wakame supplementation could be explained by different fac-
tors. For example, we could first mention the heterogeneity of 
the populations involved (obesity, diabetes, hyperlipidemia, 
healthy subjects, gender, and so on); secondly the daily amount 
of wakame or carob administered, and the type of food (functional 
food, rice, solid, beverage, and so on), were different; finally, there 
was variability in intervention regimen time. However, the results 
on LDL-cholesterol were significant when carob was used in the 
interventions. So, we could summarize this group of studies by 
noting that in the literature beneficial effects on LDL-cholester-
ol have been identified with the use of carob, without any side 
effects as demonstrated with our design. We also have to take 
into account that the effect of other snack ingredients may also 
be important in the observed results, such as the amount of fat 
or its quality. Despite all the biological effects of wakame and 
carob mentioned in this and other studies, it is necessary to take 
into account that the potential healthy effect of these foods is 
supervised by the EFSA (European Food Safety Authority), and to 
date they have issued no favorable opinion on wakame or carob. 
Limitations in our study include a small sample size and, sec-
ondly, the type of subjects enrolled (obese subjects with metabolic 
syndrome), the latter rendering our results not extrapolable to 
the general population. Thirdly, the low dose of wakame makes 
it difficult to observe effects on glucose metabolism, as has been 
demonstrated in other studies. Another limitation is the lack of 
intervention branches to analyze the snack with the functional 
ingredient individually, that is, a snack containing only wakame 
and a snack containing only carob. Finally, the presence of a high 
amount of fiber in the control snack allowed no differences to be 
shown on satiety between snacks. 
In conclusion, our study indicates that a wakame- and car-
ob-enriched snack induced a significant decrease in total cho-
lesterol, LDL-cholesterol, and resistin levels as compared to a 
control snack, without any effects on food consumption, other car-
diovascular parameters, and anthropometric parameters. Further 
research must be designed to evaluate different enriched foods 
with wakame and carob, and their potential effects on metabo-
lism. Additionally, the acceptance by the population of this type 
of food was evaluated, which in our case was good during the 
clinical trial and in a previous sensory evaluation that had been 
carried out with healthy volunteers.
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